Azithromycin, familiar to most people as the "Z-Pack," is one of the most widely prescribed antibiotics in the world. It has also carried, since 2013, an FDA warning about a rare but serious cardiac effect: prolongation of the heart's QT interval, which in vulnerable people can trigger a dangerous rhythm disturbance. This article explains what that signal actually means, where it came from, how strong the evidence is, and — most importantly — who genuinely needs to weigh it before taking the drug. The goal is not to alarm, but to give patients and families the same understanding a careful physician would want them to have before signing off on any prescription.

What the QT Interval Is, and Why It Matters

Every heartbeat is an electrical event. The QT interval, measured on an electrocardiogram (EKG), represents the time it takes the heart's ventricles to contract and then electrically "reset" before the next beat. This resetting, called repolarization, depends on potassium flowing back out of heart muscle cells through specific channels. When a drug slows that potassium outflow, repolarization takes longer, and the QT interval — corrected for heart rate, and written as QTc — stretches out.

A longer QTc is not itself a symptom or a disease. It is a marker of electrical instability. In a small number of people, an excessively prolonged QTc creates the conditions for a specific and dangerous arrhythmia called torsades de pointes — a French phrase meaning "twisting of the points," describing the rhythm's appearance on an EKG strip. Torsades usually resolves on its own, but it can also degenerate into ventricular fibrillation, a cardiac arrest requiring immediate defibrillation. This is why QT prolongation, even though it is a laboratory finding rather than an illness, is taken seriously by cardiologists and regulators alike.

How Azithromycin Affects the Heart's Electrical System

Azithromycin belongs to the macrolide family of antibiotics, derived originally from erythromycin — itself a product of a soil-dwelling actinomycete bacterium discovered in the Philippines in the late 1940s. It is worth pausing on that origin: a compound capable of treating serious bacterial infection, waiting in ordinary soil, is a small but genuine example of the intricate provision built into the natural world, later refined by chemists into azithromycin's more stable, better-tolerated form.

That refinement, however, did not eliminate a shared mechanistic quirk of the macrolide class. In laboratory studies using isolated heart cells and cloned human ion channels, azithromycin has been shown to bind — weakly, compared to some related drugs — to the hERG potassium channel, the same channel responsible for the repolarizing current described above. Blocking this channel, even partially, is the proposed mechanism behind the QT prolongation seen on EKGs in some patients taking the drug. This is a class effect: erythromycin and clarithromycin show the same property, generally more strongly than azithromycin does in these in vitro comparisons.

The Human Evidence: What the Major Studies Actually Found

Mechanism and cell-culture binding data raise a plausible concern, but the question that matters for patients is whether it translates into real-world harm. Several large studies have tried to answer that.

The pivotal one came from Vanderbilt University researchers, published in the New England Journal of Medicine in 2012. Using Tennessee Medicaid records, the team compared cardiovascular death rates among patients prescribed a five-day course of azithromycin against those prescribed no antibiotic, amoxicillin, or the fluoroquinolones ciprofloxacin and levofloxacin. They found a statistically significant increase in cardiovascular death during the azithromycin treatment window — roughly 47 additional cardiovascular deaths per million courses compared with amoxicillin in the general study population, rising substantially higher, to roughly 245 additional deaths per million courses, among patients already in the highest decile of baseline cardiovascular risk. This study, based on real prescribing data across tens of thousands of patients, was the primary basis for the FDA's March 2013 Drug Safety Communication warning about azithromycin and QT prolongation.

It is important to note what this study could and could not show. As an observational cohort study, it cannot fully rule out confounding — the possibility that patients prescribed azithromycin differed in some unmeasured way from those prescribed amoxicillin. A large Danish national registry study, published in the same journal the following year, partially addressed this by comparing azithromycin to penicillin V in a broader, younger, and healthier adult population; it found no statistically significant increase in cardiovascular death associated with azithromycin in that lower-risk group, though it did find an increased risk when azithromycin users were compared to people taking no antibiotic at all — a comparison more susceptible to confounding by the underlying infection itself. Taken together, the honest reading of the evidence is this: the signal is real and mechanistically sound, but the absolute risk in a young, healthy person with no cardiac history appears to be very small, while it rises meaningfully in people who already carry cardiovascular risk factors.

A more recent and directly relevant body of evidence emerged during the COVID-19 pandemic, when azithromycin was studied in combination with hydroxychloroquine — a pairing explored, though never FDA-approved, for COVID-19 treatment. Hospital-based studies from that period consistently found that combining the two drugs produced a larger QTc prolongation than either drug alone, prompting cardiac monitoring protocols in hospitalized patients who received the combination. This is a useful, if sobering, real-world illustration of how QT-prolonging drugs can stack on one another.

Who Is Actually at Risk

The overwhelming majority of people who take a short course of azithromycin for a sinus infection, bronchitis, or a sexually transmitted infection will never notice any cardiac effect, and the FDA has never recommended withholding the drug from the general population. The risk concentrates in identifiable groups. Recognized risk factors include:

For someone with none of these factors, azithromycin's cardiac risk profile is reassuring. For someone with several of them stacked together — an elderly patient on a diuretic and an antiarrhythmic, for instance — the calculation changes, and that is precisely the kind of situation a physician should be actively thinking through, not simply defaulting to habit because azithromycin is convenient and well tolerated in most other respects.

Azithromycin Compared to Other Macrolides

Context matters here. Erythromycin, the oldest member of this drug family, has the longest and most convincing record of QT-related risk, partly because of its own hERG channel effects and partly because it strongly inhibits the liver enzyme CYP3A4, raising blood levels of many other drugs it is combined with. Clarithromycin shares that enzyme-inhibiting property and carries its own well-documented QT signal, along with a 2018 Health Canada and subsequent FDA-reviewed concern about long-term cardiovascular mortality risk in patients with coronary artery disease. Azithromycin is comparatively favorable on both counts: it is a weaker hERG channel blocker in laboratory studies and it does not meaningfully inhibit CYP3A4, which is one reason clinicians often reach for it over its older relatives, particularly in patients already taking multiple medications. That comparative advantage is real, but it is a matter of degree, not a clean bill of health — azithromycin still appears on every major list of drugs with a recognized, if conditional, risk of QT prolongation.

Making an Informed Decision

None of this evidence supports avoiding azithromycin reflexively, and none of it supports prescribing it thoughtlessly. The responsible position, consistent with genuine informed consent, is that patients deserve to know this risk exists, understand roughly how large it is for someone in their own situation, and have the chance to ask their physician direct questions before taking the drug — particularly if they have a personal or family cardiac history, take other medications, or are prescribed azithromycin repeatedly rather than occasionally. A baseline EKG is not routinely necessary before a short course in a healthy adult, but it is a reasonable request for anyone with the risk factors listed above, and a reasonable physician will not be offended by the question. Families managing chronic illness or caring for elderly relatives are well served by keeping a written list of all current medications on hand, precisely so that additive risks like this one can be caught before a prescription is filled rather than after a symptom appears.

Key takeaway: Azithromycin carries a small, mechanistically real risk of QT prolongation that matters most for people with existing heart disease, electrolyte problems, or other QT-prolonging medications — a risk worth naming plainly so patients and their doctors can make an informed choice together, without either dismissing it or overstating it.